Gilbert's syndrome and irinotecan toxicity: Combination with UDP-glucuronosyltransferase 1A7 variants increases risk

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 3, 2008, Pages 695-701

  Lankisch, Tim O ^a   Schulz, Christoph ^b   Zwingers, Thomas ^c   Erichsen, Thomas J ^a   Manns, Michael P ^a   Heinemann, Volker ^c   Strassburg, Christian P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Fa Estimate GmbH Augsburg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLIC ACID; GLUCURONOSYLTRANSFERASE 1A7; IRINOTECAN; OXALIPLATIN;

ADULT; ALLELE; ANEMIA; ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG DOSE REDUCTION; FEMALE; GENETIC VARIABILITY; GENOTYPE; GILBERT DISEASE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; WEIGHT REDUCTION; WORLD HEALTH ORGANIZATION;

EID: 41549134617     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-2517     Document Type: Article

References (21)

1. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7.
2. Folprecht G, Kohne CH. The role of new agents in the treatment of colorectal cancer. Oncology 2004;66:1-17.
3. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991;51:4187-91.
4. Ciotti M, Basu N, Brangi M, Owens IS. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus. Biochem Biophys Res Commun 1999;260:199-202.
5. Iyer L, King CD, Whitington PF, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998;101:847-54.
6. Innocenti F, Ratain MJ. Irinotecan treatment in cancer patients with UGT1A1 polymorphisms. Oncology (Huntingt) 2003;17:52-5.
7. Ando Y, Saka H, Asai G, Sugiura S, Shimokata K, Kamataki T. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann Oncol 1998;9:845-7.
8. Gagne JF, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 2002;62:608-17.
9. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDPglucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004;22:1382-8.
10. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 2000;40:581-616.
11. Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995;333:1171-5.
12. Guillemette C, Ritter JK, Auyeung DJ, Kessler FK, Housman DE. Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene. Pharmacogenetics 2000;10:629-44.
13. Lankisch TO, Moebius U, Wehmeier M, et al. Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype. Hepatology 2006;44:1324-32.
14. Lankisch TO, Vogel A, Eilermann S, et al. Identification and characterization of a functional TATA box polymorphism of the UDP glucuronosyltransferase 1A7 gene. Mol Pharmacol 2005;67:1732-9.
15. Strassburg CP, Vogel A, Kneip S, Tukey RH, Manns MP. Polymorphisms of the UDP-glucuronosyltransferase (UGT) 1A7 gene in colorectal cancer. Gut 2002;50:851-56.
16. Marcuello E, Altes A, Menoyo A, Del Rio E, Gomez-Pardo M, Baiget M. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 2004;91:678-82.
17. Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 2004;10:5151-9.
18. Carlini LE, Meropol NJ, Bever J, et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 2005;11:1226-36.
19. Tallman MN, Miles K, Kessler F, et al. The contribution of intestinal UDP-glucuronosyltransferases in modulating SN-38 induced gastrointestinal toxicity in rats. J Pharmacol Exp Ther 2006.
20. Ando M, Ando Y, Sekido Y, Shimokata K, Hasegawa Y. Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients. Jpn J Cancer Res 2002;93:591-7.
21. Tang KS, Chiu HF, Chen HH, et al. Link between colorectal cancer and polymorphisms in the uridine-diphosphoglucuronosyltransferase 1A7 and 1A1 genes. World J Gastroenterol 2005;11:3250-4.